A BSTRACT This article presents a detailed analysis of the herbal medicinal product market in the Republic of Kazakhstan from 2020 to 2024. The study examines key factors influencing market development, including assortment composition, the competitive landscape, retail sales dynamics, and the balance between imported and domestically produced herbal medicines. The findings show that only 54 herbal medicinal products with ATC codes are registered, representing 0.77% of all medicines, with domestic production remaining limited at around 15% of the market. The assortment is dominated by R05 cough and cold preparations, followed by sedatives, general tonics, and digestive system agents. Retail data indicate stable demand, with notable growth in solid dosage forms and a recent decline in liquid forms. The analysis highlights Kazakhstan’s continued dependence on foreign manufacturers and underscores the need to strengthen domestic phytopharmaceutical production to leverage the country’s significant botanical potential.
Izteleuova et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: